CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
exploiting the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases, announced today that
its Chief Executive Officer, Dr. Joseph Sarret, will present a
company overview at the H.C. Wainwright 24th Annual Global
Investment Conference, being held September 12 - 14, 2022.
H.C. Wainwright
24th Annual Global Investment
Conference
- Webcast: The
presentation may be accessed via webcast on demand using the
following link:
https://journey.ct.events/view/3624e126-052f-4eb6-8e8c-6d49842dff18
A replay of the webcast will be available in the events section
of the CohBar website for two weeks following the presentation.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage
biotechnology company leveraging the power of the mitochondria and
the peptides encoded in its genome to develop potential
breakthrough therapeutics targeting chronic and age-related
diseases with limited to no treatment options. CohBar has assembled
a leading position in exploring the mitochondrial genome and its
utility for the development of novel therapeutics, including
world-renowned expertise in mitochondrial biology, a broad
intellectual property estate, key opinion leaders and disciplined
drug discovery and development processes. CohBar is utilizing its
Mito+ platform to identify and develop modified versions of natural
peptides called analogs to treat a variety of serious conditions,
with a focus on diseases involving inflammation and fibrosis.
CohBar is planning to file an IND for its second clinical candidate
CB5138-3 in the second half of 2023, with an initial indication of
idiopathic pulmonary fibrosis. The company has previously
demonstrated clinical proof of concept for its approach with the
positive topline data from its CB4211 product candidate being
developed for NASH and obesity.
For additional company information, please visit www.cohbar.com
and engage with us on LinkedIn.
Forward-Looking Statements
This news release contains forward-looking
statements that are not historical facts within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and other future
conditions. In some cases you can identify these statements by
forward-looking words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “should,” “would,”
“project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or
the negative or plural of these words or similar expressions.
Examples of such forward-looking statements include but are not
limited to statements regarding ongoing and planned research and
development activities, including planned clinical trials,
regulatory status and strategies and the timing of announcements
and updates relating to our regulatory filings and clinical trials;
and statements regarding anticipated therapeutic properties and
potential of our mitochondrial peptide analogs and other potential
therapies. You are cautioned that such statements are not
guarantees of future performance and that actual results or
developments may differ materially from those set forth in these
forward-looking statements. Factors that could cause actual results
to differ materially from these forward-looking statements include:
our ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials and the timing of announcements and updates relating to our
clinical trials and related data; our possible inability to
mitigate the prevalence and/or persistence of the injection site
reactions, or the possibility of other developments affecting the
viability of CB4211 or CB5138-3 as a clinical candidate or its
commercial potential; results that are different from earlier data
results including less favorable results that may not support
further clinical development; our ability to raise additional
capital when necessary to continue our operations; our ability to
recruit and retain key management and scientific personnel; the
risk that our intellectual property may not be adequately
protected; our ability to establish and maintain partnerships with
corporate and industry partners; and risks related to the impact on
our business of the COVID-19 pandemic or similar public health
crises. Additional assumptions, risks and uncertainties are
described in detail in our registration statements, reports and
other filings with the Securities and Exchange Commission and
applicable Canadian securities regulators, which are available on
our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Aug 2024 to Sep 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Sep 2023 to Sep 2024